Managing of giant cell arteritis and polymyalgia rheumatica

References

• Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261–271.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–1461.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore). 2007;86:61–68.
   PubMed Web of Science ®Google Scholar
• Carmona FD, Martín J, González-Gay MA. Genetics of vasculitis. Curr OpinRheumatol. 2015;27:10–17.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Amoli MM, Garcia-Porrua C, et al. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003;33:38–48.
   PubMed Web of Science ®Google Scholar
• Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311–317.
   PubMed Web of Science ®Google Scholar
• Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54:463–470.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum. 1991;42:844–853.
   Web of Science ®Google Scholar
• Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005;84:269–276.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79:283–292.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125:509–520.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;125:521–526.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore). 2009;88:227–235.
   PubMed Web of Science ®Google Scholar
• Pego-Reigosa R, Garcia-Porrua C, Piñeiro A, et al. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S13–17.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83:335–341.
   PubMed Web of Science ®Google Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, et al. and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3522–3531.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum. 2004;33:289–293.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol. 1998;25:1750–1755.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA. The diagnosis and management of patients with giant cell arteritis. J Rheumatol. 2005;32:1186–1188.
   PubMed Web of Science ®Google Scholar
• Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–1128.
   PubMed Web of Science ®Google Scholar
• Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982;97:672–680.
   PubMed Web of Science ®Google Scholar
• Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum. 1984;13:322–328.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Rodríguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med. 1997;157:317–320.
   PubMedGoogle Scholar
• Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med. 1997;127:27–31.
   PubMed Web of Science ®Google Scholar
• Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol. 2001;28:1049–1055.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol. 2005;23:462–468.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Barozzi L, Cantini F, et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis. 2008;67:758–761.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64:943–954.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2015;67:2569–2580.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol. 2000;27:2179–2184.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Llorca J. Clinical guidelines: best practices and uncertainties in the management of PMR. Nat Rev Rheumatol. 2016;12:3–4.
   PubMed Web of Science ®Google Scholar
• Camellino D, Cimmino MA. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford). 2012;51:77–86.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Duftner C, Buttgereit F, et al. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2016;(Aug 1):pii: kew273. [Epub ahead of print].
   PubMedGoogle Scholar
• Loricera J, Blanco R, Hernández JL, et al. Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-19-31.
   Web of Science ®Google Scholar
• Saleh M, Turesson C, Englund M, et al. Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study. J Rheumatol. 2016;43:1559–1565.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Castañeda S, Llorca J. Giant cell arteritis: visual loss is our major concern. J Rheumatol. 2016;43:1458–1461.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Piñeiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004;83:342–347.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford). 2009;48:250–253.
   PubMed Web of Science ®Google Scholar
• Mackie SL, Dasgupta B, Hordon L, et al. UK GCA consortium. Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. Rheumatology (Oxford). 2011;50:2014–2022.
   PubMed Web of Science ®Google Scholar
• Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332–1337.
   PubMed Web of Science ®Google Scholar
• Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54:3306–3309.
   PubMed Web of Science ®Google Scholar
• Narváez J, Bernad B, Gómez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S57–62.
   PubMed Web of Science ®Google Scholar
• Berger CT, Wolbers M, Meyer P, et al. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford). 2009;48:258–261.
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, López-Hoyos M, Narvaez J, et al. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev. 2014;13:788–794.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Salvarani C, et al. Polymyalgia manifestations in different conditions mimicking polymyalgia rheumatica. Clin Exp Rheumatol. 2000;18:755–759.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. Diagnostic approach in a patient presenting with polymyalgia. Clin Exp Rheumatol. 1999;17:276–278.
   PubMed Web of Science ®Google Scholar
• Martinez-Lado L, Calviño-Díaz C, Piñeiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011;90:186–193.
   PubMed Web of Science ®Google Scholar
• Restuccia G, Boiardi L, Cavazza A, et al. Flares in biopsy-proven giant cell arteritis in Northern Italy: characteristics and predictors in a long-term follow-up study. Medicine (Baltimore). 2016;95:e3524.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Vázquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol. 1999;26:1326–1332.
   PubMed Web of Science ®Google Scholar
• Kremers HM, Reinalda MS, Crowson CS, et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32:65–73.
   PubMed Web of Science ®Google Scholar
• Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49:703–708.
   PubMed Web of Science ®Google Scholar
• Hernández-Rodríguez J, García-Martínez A, Casademont J, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 2002;47:29–35.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Pina T. Giant cell arteritis and polymyalgia rheumatica: an update. Curr Rheumatol Rep. 2015;17:6.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Martinez-Dubois C, Agudo M, et al. Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep. 2010;12:436–442.
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497–1504.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand. 2002;80:355–367.
   PubMedGoogle Scholar
• Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310–3318.
   PubMed Web of Science ®Google Scholar
• Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27:1484–1491.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003;110:1204–1215.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Miranda-Filloy JA, et al. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management. DrugsAging. 2006;23:627–649.
   Google Scholar
• Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003;217:239–259.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50–57.
   PubMed Web of Science ®Google Scholar
• Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol. 2001;30:260–267.
   PubMed Web of Science ®Google Scholar
• Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis, I: steroid regimens in the first two months. Ann Rheum Dis. 1989;48:658–661.
   PubMed Web of Science ®Google Scholar
• Di Munno O, Imbimbo B, Mazzantini M, et al. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. J Rheumatol. 1995;22:1492–1498.
   PubMed Web of Science ®Google Scholar
• Krogsgaard MR, Lund B, Johnsson B. A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol. 1995;22:1660–1662.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Olivieri I, et al. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol. 2000;27:1470–1476.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Dolan AL, Panayi GS, et al. An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol. 1998;37:189–195.
   PubMedGoogle Scholar
• Yates M, Loke YK, Watts RA, et al. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clin Rheumatol. 2014;33:227–236.
   PubMed Web of Science ®Google Scholar
• Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495–501.
   PubMed Web of Science ®Google Scholar
• Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106–114.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309–1318.
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789–2797.
   PubMed Web of Science ®Google Scholar
• Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996;55:218–223.
   PubMed Web of Science ®Google Scholar
• Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141:493–500.
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996;23:624–628.
   PubMed Web of Science ®Google Scholar
• De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45:136–138.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay M. The quest for the ideal therapy for giant cell arteritis. Rev Rhum Engl Ed. 1995;62:539.
   PubMedGoogle Scholar
• Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:1–3.
   Web of Science ®Google Scholar
• Kötter I, Henes JC, Wagner AD, et al. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S114–29.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621–630.
   PubMed Web of Science ®Google Scholar
• Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomized controlled trial. Ann Rheum Dis. 2014;73:2074–2081.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Niccoli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol. 2003;30:760–763.
   PubMed Web of Science ®Google Scholar
• Migliore A, Massafra U, Carloni E, et al. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci. 2005;9:373–378.
   PubMedGoogle Scholar
• Aikawa NE, Pereira RM, Lage L, et al. Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature. Clin Rheumatol. 2012;31:575–579.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484–491.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res. 2010;62:835–841.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041–1048.
   PubMed Web of Science ®Google Scholar
• Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol. 2013;25:3–9.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum. 2015;44:717–723.
   PubMed Web of Science ®Google Scholar
• Régent A, Redeker S, Deroux A, et al. Tocilizumab in GIANT cell arteritis: a multicenter retrospective study of 34 patients. J Rheumatol. 2016;43:1547–1552.
   PubMed Web of Science ®Google Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–1927.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Castañeda S, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S79–89.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S44–53.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Biologic therapy in ANCA-negative vasculitis. Int Immunopharmacol. 2015;27:213–219.
   PubMed Web of Science ®Google Scholar
• Macchioni P, Boiardi L, Catanoso M, et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum. 2013;43:113–118.
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75:1506–1510.
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Adachi JD, Cooper C, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2012;91:225–243.
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol. 2015;11:98–109.
   PubMed Web of Science ®Google Scholar
• Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73–81.
   PubMed Web of Science ®Google Scholar
• Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319–1328.
   PubMed Web of Science ®Google Scholar
• Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis. 2005;64:176–178.
   PubMed Web of Science ®Google Scholar
• Oxlund H, Ortoft G, Thomsen JS, et al. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone. 2006;39:244–252.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015;75:222–228.
   PubMed Web of Science ®Google Scholar
• Ortego-Jurado M, Callejas-Rubio JL, Ríos-Fernández R, et al. Oral calcidiol is more effective than cholecalciferol supplementation to reach adequate 25(OH)D levels in patients with autoimmune diseases chronically treated with low doses of glucocorticoids: a “real-life” study. J Osteoporos. 2015;2015:1–7.
   Google Scholar
• Pérez-Esteban S, González-Gay MA, Castañeda S. Therapeutic update in large vessel vasculitides. Rev Clin Esp (Barc). 2013;213:338–346.
   PubMed Web of Science ®Google Scholar